Cargando…

Proteomic as an Exploratory Approach to Develop Vaccines Against Tick-Borne Diseases Using Lyme Borreliosis as a Test Case

Tick-borne diseases affecting humans and animals are on the rise worldwide. Vaccines constitute an effective control measure, but very few are available. We selected Lyme borreliosis, a bacterial infection transmitted by the hard tick Ixodes, to validate a new concept to identify vaccine candidates....

Descripción completa

Detalles Bibliográficos
Autores principales: Talagrand-Reboul, Emilie, Westermann, Benoit, Raess, Matthieu A., Schnell, Gilles, Cantero, Paola, Barthel, Cathy, Ehret-Sabatier, Laurence, Jaulhac, Benoit, Boulanger, Nathalie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564290/
https://www.ncbi.nlm.nih.gov/pubmed/32825641
http://dx.doi.org/10.3390/vaccines8030463
_version_ 1783595680390971392
author Talagrand-Reboul, Emilie
Westermann, Benoit
Raess, Matthieu A.
Schnell, Gilles
Cantero, Paola
Barthel, Cathy
Ehret-Sabatier, Laurence
Jaulhac, Benoit
Boulanger, Nathalie
author_facet Talagrand-Reboul, Emilie
Westermann, Benoit
Raess, Matthieu A.
Schnell, Gilles
Cantero, Paola
Barthel, Cathy
Ehret-Sabatier, Laurence
Jaulhac, Benoit
Boulanger, Nathalie
author_sort Talagrand-Reboul, Emilie
collection PubMed
description Tick-borne diseases affecting humans and animals are on the rise worldwide. Vaccines constitute an effective control measure, but very few are available. We selected Lyme borreliosis, a bacterial infection transmitted by the hard tick Ixodes, to validate a new concept to identify vaccine candidates. This disease is the most common tick-borne disease in the Northern Hemisphere. Although attempts to develop a vaccine exist, none have been successfully marketed. In tick-borne diseases, the skin constitutes a very specific environment encountered by the pathogen during its co-inoculation with tick saliva. In a mouse model, we developed a proteomic approach to identify vaccine candidates in skin biopsies. We identified 30 bacterial proteins after syringe inoculation or tick inoculation of bacteria. Discovery proteomics using mass spectrometry might be used in various tick-borne diseases to identify pathogen proteins with early skin expression. It should help to better develop sub-unit vaccines based on a cocktail of several antigens, associated with effective adjuvant and delivery systems of antigens. In all vector-borne diseases, the skin deserves further investigation to better define its role in the elaboration of protective immunity against pathogens.
format Online
Article
Text
id pubmed-7564290
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-75642902020-10-26 Proteomic as an Exploratory Approach to Develop Vaccines Against Tick-Borne Diseases Using Lyme Borreliosis as a Test Case Talagrand-Reboul, Emilie Westermann, Benoit Raess, Matthieu A. Schnell, Gilles Cantero, Paola Barthel, Cathy Ehret-Sabatier, Laurence Jaulhac, Benoit Boulanger, Nathalie Vaccines (Basel) Article Tick-borne diseases affecting humans and animals are on the rise worldwide. Vaccines constitute an effective control measure, but very few are available. We selected Lyme borreliosis, a bacterial infection transmitted by the hard tick Ixodes, to validate a new concept to identify vaccine candidates. This disease is the most common tick-borne disease in the Northern Hemisphere. Although attempts to develop a vaccine exist, none have been successfully marketed. In tick-borne diseases, the skin constitutes a very specific environment encountered by the pathogen during its co-inoculation with tick saliva. In a mouse model, we developed a proteomic approach to identify vaccine candidates in skin biopsies. We identified 30 bacterial proteins after syringe inoculation or tick inoculation of bacteria. Discovery proteomics using mass spectrometry might be used in various tick-borne diseases to identify pathogen proteins with early skin expression. It should help to better develop sub-unit vaccines based on a cocktail of several antigens, associated with effective adjuvant and delivery systems of antigens. In all vector-borne diseases, the skin deserves further investigation to better define its role in the elaboration of protective immunity against pathogens. MDPI 2020-08-21 /pmc/articles/PMC7564290/ /pubmed/32825641 http://dx.doi.org/10.3390/vaccines8030463 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Talagrand-Reboul, Emilie
Westermann, Benoit
Raess, Matthieu A.
Schnell, Gilles
Cantero, Paola
Barthel, Cathy
Ehret-Sabatier, Laurence
Jaulhac, Benoit
Boulanger, Nathalie
Proteomic as an Exploratory Approach to Develop Vaccines Against Tick-Borne Diseases Using Lyme Borreliosis as a Test Case
title Proteomic as an Exploratory Approach to Develop Vaccines Against Tick-Borne Diseases Using Lyme Borreliosis as a Test Case
title_full Proteomic as an Exploratory Approach to Develop Vaccines Against Tick-Borne Diseases Using Lyme Borreliosis as a Test Case
title_fullStr Proteomic as an Exploratory Approach to Develop Vaccines Against Tick-Borne Diseases Using Lyme Borreliosis as a Test Case
title_full_unstemmed Proteomic as an Exploratory Approach to Develop Vaccines Against Tick-Borne Diseases Using Lyme Borreliosis as a Test Case
title_short Proteomic as an Exploratory Approach to Develop Vaccines Against Tick-Borne Diseases Using Lyme Borreliosis as a Test Case
title_sort proteomic as an exploratory approach to develop vaccines against tick-borne diseases using lyme borreliosis as a test case
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564290/
https://www.ncbi.nlm.nih.gov/pubmed/32825641
http://dx.doi.org/10.3390/vaccines8030463
work_keys_str_mv AT talagrandreboulemilie proteomicasanexploratoryapproachtodevelopvaccinesagainsttickbornediseasesusinglymeborreliosisasatestcase
AT westermannbenoit proteomicasanexploratoryapproachtodevelopvaccinesagainsttickbornediseasesusinglymeborreliosisasatestcase
AT raessmatthieua proteomicasanexploratoryapproachtodevelopvaccinesagainsttickbornediseasesusinglymeborreliosisasatestcase
AT schnellgilles proteomicasanexploratoryapproachtodevelopvaccinesagainsttickbornediseasesusinglymeborreliosisasatestcase
AT canteropaola proteomicasanexploratoryapproachtodevelopvaccinesagainsttickbornediseasesusinglymeborreliosisasatestcase
AT barthelcathy proteomicasanexploratoryapproachtodevelopvaccinesagainsttickbornediseasesusinglymeborreliosisasatestcase
AT ehretsabatierlaurence proteomicasanexploratoryapproachtodevelopvaccinesagainsttickbornediseasesusinglymeborreliosisasatestcase
AT jaulhacbenoit proteomicasanexploratoryapproachtodevelopvaccinesagainsttickbornediseasesusinglymeborreliosisasatestcase
AT boulangernathalie proteomicasanexploratoryapproachtodevelopvaccinesagainsttickbornediseasesusinglymeborreliosisasatestcase